share_log

18 Analysts Have This To Say About Crinetics Pharmaceuticals

Benzinga ·  May 15 00:00

In the last three months, 18 analysts have published ratings on Crinetics Pharmaceuticals (NASDAQ:CRNX), offering a diverse range of perspectives from bullish to bearish.

The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.

BullishSomewhat BullishIndifferentSomewhat BearishBearish
Total Ratings711000
Last 30D01000
1M Ago12000
2M Ago33000
3M Ago35000

The 12-month price targets, analyzed by analysts, offer insights with an average target of $62.78, a high estimate of $97.00, and a low estimate of $48.00. This upward trend is apparent, with the current average reflecting a 24.89% increase from the previous average price target of $50.27.

price target chart

Breaking...

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment